HOTH: Hoth Therapeutics, Inc. Stock

by  •  • Comments Off on HOTH: Hoth Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 10.19
Enterprise Value ($M) 3.15
Book Value ($M) 6.88
Book Value / Share 0.52
Price / Book 1.48
NCAV ($M) 6.81
NCAV / Share 0.52
Price / NCAV 1.50

Profitability (mra)
Return on Invested Capital (ROIC) -1.19
Return on Assets (ROA) -0.96
Return on Equity (ROE) -1.05

Liquidity (mrq)
Quick Ratio 9.20
Current Ratio 9.20

Balance Sheet (mrq) ($M)
Current Assets 7.64
Assets 7.71
Liabilities 0.83
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -8.22
Net Income -8.19
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -6.98
Cash from Investing 0.00
Cash from Financing 4.74

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: September 30, 2024 ☐ TRANSITION REP
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: June 30, 2024 ☐ TRANSITION REPORT P
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended: March 31, 2024 ☐ TRANSITION REPORT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 57,715 360,635 16.00
2025-04-16 31,736 166,273 19.09
2025-04-15 114,697 439,954 26.07

(click for more detail)

Similar Companies
HCWB – HCW Biologics Inc. HEPA – Hepion Pharmaceuticals, Inc.
HOOK – HOOKIPA Pharma Inc. HRTX – Heron Therapeutics, Inc.
IBIO – iBio, Inc.


Financial data and stock pages provided by
Fintel.io